NCT04315818

Brief Summary

Rheumatoid Arthritis is a chronic debilitating inflammatory autoimmune disease of unknown etiology .

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2021

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 18, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 20, 2020

Completed
12 months until next milestone

Study Start

First participant enrolled

March 1, 2021

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2023

Completed
Last Updated

January 26, 2021

Status Verified

March 1, 2020

Enrollment Period

2.5 years

First QC Date

March 18, 2020

Last Update Submit

January 24, 2021

Conditions

Rheumatoid Arthritis

Outcome Measures

Primary Outcomes (1)

  • The Relation Between Macrophage Migration Inhibitory Factor (MIF) and 25(OH) Vitamin D3 Serum Levels in Rheumatoid Arthritis

    * evaluate the role of Macrophage Migration Inhibitory Factor serum levels in Rheumatoid Arthritis and its relation with disease activity. * evaluate the role of 25(OH)vitamin D3 serum levels in Rheumatoid Arthritis patients and its relation to disease severity. * detect the relationship between Macrophage Migration Inhibitory Factor and 25(OH)vitamin D3 serum levels in Rheumatoid Arthritis patients

    october,2022

Study Arms (2)

study group

expermintal

control group

placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Any patient aged 18 or older and satisfying 2010 ACR/ EULAR Rheumatoid Arthritis classification criteria will be included

You may qualify if:

  • Any patient aged 18 or older
  • satisfying 2010 ACR/ EULAR Rheumatoid Arthritis classification criteria will be included .

You may not qualify if:

  • Any patient with arthritis other than Rheumatoid Arthritis
  • Individuals with other autoimmune diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (5)

  • Santos LL, Morand EF. The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien Med Wochenschr. 2006 Jan;156(1-2):11-8. doi: 10.1007/s10354-005-0243-8.

    PMID: 16465610BACKGROUND

  • Kim KW, Kim HR. Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis. Korean J Intern Med. 2016 Jul;31(4):634-42. doi: 10.3904/kjim.2016.098. Epub 2016 May 12.

    PMID: 27169879BACKGROUND

  • Llamas-Covarrubias MA, Valle Y, Navarro-Hernandez RE, Guzman-Guzman IP, Ramirez-Duenas MG, Rangel-Villalobos H, Estrada-Chavez C, Munoz-Valle JF. Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int. 2012 Aug;32(8):2307-11. doi: 10.1007/s00296-011-1951-6. Epub 2011 May 24.

    PMID: 21607559BACKGROUND

  • Ishikawa LLW, Colavite PM, Fraga-Silva TFC, Mimura LAN, Franca TGD, Zorzella-Pezavento SFG, Chiuso-Minicucci F, Marcolino LD, Penitenti M, Ikoma MRV, Sartori A. Vitamin D Deficiency and Rheumatoid Arthritis. Clin Rev Allergy Immunol. 2017 Jun;52(3):373-388. doi: 10.1007/s12016-016-8577-0.

    PMID: 27484684BACKGROUND

  • Bilsborrow JB, Doherty E, Tilstam PV, Bucala R. Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus. Expert Opin Ther Targets. 2019 Sep;23(9):733-744. doi: 10.1080/14728222.2019.1656718. Epub 2019 Aug 20.

    PMID: 31414920BACKGROUND

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Doaa Kamal, Doctor

    Assiut University

    STUDY CHAIR

Central Study Contacts

Eman Ahmed, professor

CONTACT

01066643425e_omran@hotmail.com

Marwa Ahmed, Assistant professor

CONTACT

01006783422marwa.a.galal@aun.edu.eg

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investegator

Study Record Dates

First Submitted

March 18, 2020

First Posted

March 20, 2020

Study Start

March 1, 2021

Primary Completion

September 1, 2023

Study Completion

September 1, 2023

Last Updated

January 26, 2021

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will share